



Year: 2014

The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation

Moes, Arthur D ; van der Lubbe, Nils ; Zietse, Robert ; Loffing, Johannes ; Hoorn, Ewout J

Abstract: SLC12A3 encodes the thiazide-sensitive sodium chloride cotransporter (NCC), which is primarily expressed in the kidney, but also in intestine and bone. In the kidney, NCC is located in the apical plasma membrane of epithelial cells in the distal convoluted tubule. Although NCC reabsorbs only 5 to 10 % of filtered sodium, it is important for the fine-tuning of renal sodium excretion in response to various hormonal and non-hormonal stimuli. Several new roles for NCC in the regulation of sodium, potassium, and blood pressure have been unraveled recently. For example, the recent discoveries that NCC is activated by angiotensin II but inhibited by dietary potassium shed light on how the kidney handles sodium during hypovolemia (high angiotensin II) and hyperkalemia. The additive effect of angiotensin II and aldosterone maximizes sodium reabsorption during hypovolemia, whereas the inhibitory effect of potassium on NCC increases delivery of sodium to the potassium-secreting portion of the nephron. In addition, great steps have been made in unraveling the molecular machinery that controls NCC. This complex network consists of kinases and ubiquitinases, including WNKs, SGK1, SPAK, Nedd4-2, Cullin-3, and Kelch-like 3. The pathophysiological significance of this network is illustrated by the fact that modification of each individual protein in the network changes NCC activity and results in salt-dependent hypotension or hypertension. This review aims to summarize these new insights in an integrated manner while identifying unanswered questions.

DOI: <https://doi.org/10.1007/s00424-013-1407-9>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-88126>

Journal Article

Accepted Version

Originally published at:

Moes, Arthur D; van der Lubbe, Nils; Zietse, Robert; Loffing, Johannes; Hoorn, Ewout J (2014). The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation. *Pflügers Archiv : European Journal of Physiology*, 466(1):107-118.

DOI: <https://doi.org/10.1007/s00424-013-1407-9>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

19 November 2013 – Revised version (changes in bold red font)

The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation

Arthur D. Moes¹, Nils van der Lubbe¹, Robert Zietse¹, Johannes Loffing^{2,3}, Ewout J. Hoorn¹

¹Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

²Institute of Anatomy, University of Zürich, Zürich, Switzerland, ³Zurich Centre for Integrative
Human Physiology

Manuscript type : This article is published as part of the Special Issue on sodium-dependent transporters in health and disease

Number of figures : 4

Number of tables : 2

Word count : 3884

Corresponding author:

Ewout J Hoorn, MD, PhD E-mail : e.j.hoorn@erasmusmc.nl

PO Box 2040 – Room H-438 Phone : +31-10-7032860

3000 CA Rotterdam, The Netherlands Fax : +31-10-7033008

Summary (word count: 228)

SLC12A3 encodes the thiazide-sensitive sodium chloride cotransporter (NCC), which is primarily expressed in the kidney, but also in intestine and bone. In the kidney, NCC is located in the apical plasma membrane of epithelial cells in the distal convoluted tubule. Although NCC reabsorbs only 5 to 10% of filtered sodium, it is important for the fine-tuning of renal sodium excretion in response to various hormonal and non-hormonal stimuli. Several new roles for NCC in the regulation of sodium, potassium, and blood pressure have been unraveled recently. For example, the recent discoveries that NCC is activated by angiotensin II but inhibited by dietary potassium sheds light on how the kidney handles sodium during hypovolemia (high angiotensin II) and hyperkalemia. The additive effect of angiotensin II and aldosterone maximizes sodium reabsorption during hypovolemia, whereas the inhibitory effect of potassium on NCC increases delivery of sodium to the potassium-secreting portion of the nephron. In addition, great steps have been made in unraveling the molecular machinery that controls NCC. This complex network consists of kinases and ubiquitinases, including WNKs, SGK1, SPAK, Nedd4-2, Cullin-3 and Kelch-like 3. The pathophysiological significance of this network is illustrated by the fact that modification of each individual protein in the network changes NCC activity and results in salt-dependent hypotension or hypertension. This review aims to summarize these new insights in an integrated manner while identifying unanswered questions.

Keywords: Aldosterone; Angiotensin II; Hypertension; Tacrolimus; Thiazide; WNK kinase.

Typical hallmarks of NCC

The presence of a sodium chloride cotransporter was first suggested in urinary bladder of the winter flounder [95, 96]. Subsequent studies in this tissue demonstrated that this cotransporter could be inhibited by thiazide diuretics [111] and the cDNA encoding this transporter was isolated [31].

Studies using micropuncture and isolated perfused tubules had identified the same pharmacological and kinetic transport characteristics in the early distal convoluted tubule (DCT) of rat kidney [23, 60]. Indeed, Gamba and colleagues succeeded in isolating cDNA of the sodium chloride cotransporter from rat kidney [30]. NCC is encoded by the *SLC12A3* gene (55-kb, 26 exons) and belongs to the SLC12 family of electroneutral cation chloride cotransporters [29].

Besides the kidney, NCC was shown to be expressed in intestine and bone where it is likely involved in sodium and calcium absorption [4, 20]. It has been suggested that NCC is expressed in various other tissues but this has not been confirmed [29]. In the kidney, NCC is located in the early part of the DCT (also called DCT1) (**Figure 1**), **but gradually decreases along the later** part of the DCT (DCT2), where it co-localizes with the epithelial sodium channel (ENaC) [3].

The sodium chloride cotransporter (NCC) mediates the reabsorption of sodium across the apical membrane of the DCT (**Figure 1**) [23]. Chronic activation or inhibition of NCC is usually accompanied by morphological changes in the DCT resulting in hypertrophy or atrophy [21, 61, 66, 126]. The gradient required for sodium chloride transport through NCC is generated and maintained by the basolateral sodium-potassium ATPase pump. The potassium that enters the cell via this pump is **recycled by basolateral potassium transporters. In addition, potassium may also be** secreted apically by the renal outer medullary potassium channel (ROMK) and a potassium chloride cotransporter [133]. In addition, NCC modulates transcellular magnesium and calcium reabsorption in the DCT through interaction with the transporters TRPM6 and

1
2
3
4 TRVP5, respectively (**Figure 1**) [16, 85]. Only 5 to 10% of the filtered load of sodium is
5
6 reabsorbed in the DCT and this is primarily mediated by NCC [23]. Despite this modest
7
8 contribution to overall sodium reabsorption, the NCC in the DCT together with ENaC in the
9
10 connecting tubule (CNT) and the collecting duct (CD) fine-tunes the final concentration of
11
12 sodium chloride in the urine. **This is possible** because it is not affected by the tubuloglomerular
13
14 feedback [29]. Due to this **property**, NCC plays a pivotal role in extracellular fluid volume and
15
16
17
18
19 blood pressure control [29].
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Structure–function relationship

In humans, NCC is a membrane glycoprotein of 1,021-amino acid residues which resembles the general topology of the sodium-potassium-chloride cotransporters 1 and 2 (NKCC 1 and 2) [70]. NCC is able to form dimers, and it is likely that it functions as a dimer [18, 29]. It consists of 12 putative transmembrane (TM) spanning regions with a central hydrophobic domain (**Figure 2**). Between TM7 and TM8 there is a large extracellular hydrophilic loop that contains two glycosylation sites (N404 and N424) [50]. These glycosylation sites are essential for functioning and surface expression of NCC [40]. When glycosylation is eliminated, thiazide diuretics have much greater access to their binding sites, which suggests that glycosylation blocks the affinity for thiazides [50]. A study that interchanged the transmembrane regions between rat and flounder NCC revealed that affinity-modifying residues for chloride are located within the TM1-7 region [78]. **Especially**, a highly conserved glycine within TM4 plays a crucial role for the affinity of chloride [78]. The TM8-12 region, **distal to the extracellular loop**, is sensitive to thiazides. Site-directed mutagenesis was used to show that a single residue in TM11 defines the different affinity for thiazides between mammalian and flounder NCC [12]. Both **transmembrane regions** appear to have affinity for extracellular sodium. The central domain is flanked by a short amino-terminal domain (N-terminus) and a long carboxy-terminal domain (C-terminus) which are both located intracellularly (**Figure 2**) [29]. The N-terminus of NCC contains several conserved phosphorylation sites including threonine 46, 55 and 60 and serine 73 and 91 in humans [19]. In rats **and mice** these phosphorylation sites correspond to threonine 44, 53, 58 and serine 71, 89, **and 124**. Phosphorylation of NCC appears to determine its activity, especially at threonine 60 in humans or 58 in rat. Indeed, a mutation in threonine 60 is a common cause of Gitelman syndrome [65], the disorder resulting from NCC inactivation (see further). The

1
2
3
4 development of a knock-in mouse model with this mutation exhibits the Gitelman phenotype and
5
6 did so because mutant NCC was restricted to the cytosol [138]. Because phosphorylated NCC
7
8 has thus far only been found in the apical plasma membrane of the DCT, anchoring in the plasma
9
10 membrane seems necessary for phosphorylation to occur [91]. This suggests that, apart from
11
12 phosphorylation, the trafficking of NCC from subapical vesicles to the plasma membrane is also
13
14 important [42].
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Physiological functions

NCC is highly regulated by hormones, including aldosterone, angiotensin II, glucocorticoids, estrogen, insulin, norepinephrine, and vasopressin (**Table 1**) [13, 53, 82, 83, 91, 108, 118, 124, 125]. The fact that NCC is regulated by so many different hormones suggests that sodium reabsorption through NCC is an important homeostatic control mechanism. Aldosterone was the first hormone recognized to be capable of activating NCC [53] and the DCT is therefore part of what has been called the “aldosterone-sensitive distal nephron” (ASDN) [77], which was defined to comprise the DCT2, the CNT and the CD [67]. Experimentally, aldosterone upregulates NCC both when it is directly infused or when it is secreted in response to a low sodium diet [14, 53]. The acute effect of aldosterone only involves phosphorylation of NCC [56], whereas the chronic effect also increases the total protein abundance of NCC [53], which likely occurs independent from changes to NCC mRNA levels [1, 69, 119]. The regulation of NCC by aldosterone seems logical, because at least the endportion of the DCT expresses the enzyme 11-beta-hydroxysteroid dehydrogenase II which rapidly inactivates glucocorticoids and hence provides mineralocorticoid-sensitivity to the epithelial cells [6]. The discovery that angiotensin II is also capable of activating NCC was more surprising, because its actions were believed to be confined to the proximal tubule [75]. By adrenalectomizing rats and selectively re-infusing aldosterone or angiotensin II, we were able to dissect the stimulatory effects of angiotensin II and aldosterone on NCC [118]. In a subsequent study we showed that aldosterone did not require angiotensin II for activation of NCC, although the presence of both stimuli led to an additive response [119]. This additive response may be useful to maximize sodium reabsorption during hypovolemia, because this is characterized by elevated plasma levels of both angiotensin II and aldosterone [122]. Increased sodium reabsorption in the DCT by NCC will also decrease the delivery of

1
2
3
4 sodium to the CNT and CD [42]. Because in these segments sodium reabsorption is
5
6 electrochemically coupled to potassium secretion, decreased delivery of sodium will help
7
8 conserve potassium. In line with this, recent studies have shown that angiotensin II directly
9
10 inhibits ROMK, further contributing to potassium conservation during hypovolemia [49, 129,
11
12 140]. The effects of angiotensin II on NCC and ROMK therefore help to understand the
13
14 aldosterone paradox, the question how aldosterone increases sodium reabsorption during
15
16 hypovolemia, but potassium secretion during hyperkalemia [3, 122]. Further insight into the
17
18 aldosterone paradox comes from the effects of potassium on NCC. Recent studies have shown
19
20 that dietary potassium inhibits NCC [110, 121]. Gastric gavage of potassium in mice increased
21
22 both urinary potassium and sodium excretion [110]. This response occurred within minutes and
23
24 was independent from aldosterone, because it could also be induced in aldosterone-deficient
25
26 animals. In the kidney, this was accompanied by dephosphorylation of NCC (**Figure 4A**). The
27
28 increased delivery of sodium to the more distal nephron parts facilitates sodium–potassium
29
30 exchange and therefore kaliuresis. This “potassium-induced natriuresis” appears to constitute an
31
32 important physiological response. Namely, potassium-induced natriuresis could still be evoked
33
34 when a high potassium diet was combined with a low sodium diet [121]. This was accompanied
35
36 by a reduced abundance of total NCC; **phosphorylated NCC was also reduced, although this**
37
38 **did not reach statistical significance** (**Figure 4B**). Taken together, these **and other** recent
39
40 results seem to suggest that when the organism **is** faced with the choice between conserving
41
42 sodium or secreting potassium, it chooses the latter [27]. The focus of future research will be to
43
44 identify the signal by which dietary potassium induces NCC downregulation. Similar to high
45
46 dietary potassium, high dietary sodium also suppresses NCC [14]. This response, however, is not
47
48 as rapid as the one for high potassium diet [110] and involves a decrease in the plasma
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 membrane abundance of sodium transporters all along the nephron [28, 137]. Furthermore, the
5 effect of high dietary sodium on NCC appears to be mediated through aldosterone [14],
6
7 **although the effect of high dietary sodium on NCC has not been studied in the absence of**
8 **aldosterone.** Similarly, chronic metabolic acidosis also increases aldosterone and therefore NCC
9
10 [26]. Why other hormones such as insulin [13, 57, 108, 109], vasopressin [83, 91, 104], estrogen
11
12 [125], and norepinephrine [82] regulate NCC is less clearly defined (**Table 1**), but warrants
13
14 further study given the role of these hormones in normal physiology and human diseases such as
15
16 diabetes mellitus, obesity, and hypertension.
17
18
19
20
21
22
23
24
25

26 **The NCC signaling cascade**

27 *Kinases*

28
29
30 The intracellular signaling cascade that controls NCC activity has largely been unraveled in
31 recent years (**Figure 3**). This NCC signaling cascade consists of a multikinase network which
32
33 includes the kinases WNK, SPAK, OSR1, and SGK1 [130]. More recently, proteins involved in
34
35 ubiquitylation including Nedd4-2, Kelch-like 3, and Cullin 3 were also found to regulate NCC
36
37 [2, 7, 68, 99]. Many of these regulatory proteins were identified because mutations in their genes
38
39 result in familial hyperkalemic hypertension (FHHT, also called pseudohypoaldosteronism type II
40
41 or Gordon syndrome, see also “Relation to diseases” below). WNKs **appear to** modulate both
42
43 the “trafficking” and phosphorylation of NCC [41], **although most of our knowledge has been**
44
45 **derived from studies in oocytes.** The regulation of NCC trafficking by WNKs involves a
46
47 sequential inhibitory cascade, in which KS-WNK1 inhibits WNK1, WNK1 inhibits WNK4
48
49 [136], and WNK4 inhibits NCC [134]. The inhibition of NCC by WNK4 is not caused by
50
51 endocytosis [35], but rather by promoting lysosomal degradation [112]. This inhibition is
52
53 mediated by the ERK1/2 signaling pathway and the lysosomal targeting receptor sortilin [141],
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 142]. Interestingly, angiotensin II converts WNK4 from an inhibitor to an activator of NCC
5
6 [101]. In contrast to WNK4, WNK3 stimulates NCC [97], but its actions are less well-defined.
7
8 WNK3 and WNK4 not only have divergent effects on NCC, they also antagonize each other.
9
10 Indeed, it appears to be the ratio between WNK3 and WNK4 that determines the net effect on
11
12 NCC [135]. The phosphorylation of NCC is mediated by SPAK [79]; several WNKs interact
13
14 with SPAK and therefore indirectly control the phosphorylation-step of NCC. Interactions
15
16 between SPAK and WNK1 [79], WNK3 [34], and WNK4 [102] have been reported. However,
17
18 the brain but not the kidney isoform of WNK3 can activate NCC and does so through a SPAK-
19
20 independent mechanism [34]. Two isoforms of SPAK have been identified, including full-length
21
22 SPAK (FL-SPAK) and kidney-specific SPAK (KS-SPAK or SPAK2), of which the latter
23
24 isoform has low expression levels in the DCT [73]. KS-SPAK, which lacks the kinase domain,
25
26 inhibits FL-SPAK and OSR1, which are both known to phosphorylate NKCC2. This may
27
28 explain why in mice the knockout of SPAK results in decreased NCC phosphorylation (absence
29
30 of full-length SPAK), but increased NKCC2 phosphorylation (no inhibition of FL-SPAK or
31
32 OSR1 by KS-SPAK) [36, 73].

33
34 **SPAK deficiency, however, does not completely inhibit NCC phosphorylation [73, 139],**
35
36 **suggesting the involvement of other kinases or phosphatases.** Both SPAK isoforms are also
37
38 involved in the stimulatory effect of vasopressin on NCC and NKCC2 [83, 91]. Namely,
39
40 vasopressin stimulates FL-SPAK in the DCT to phosphorylate NCC, whereas it attenuates KS-
41
42 SPAK to allow FL-SPAK and OSR1 to phosphorylate NKCC2 [104]. Although SGK1 was first
43
44 recognized as an activator of ENaC [127], later reports also showed effects on NCC [115]. SGK1
45
46 and NCC do not seem to interact directly, but rather through WNK4 and Nedd4-2 [2, 98]. SGK1
47
48 phosphorylates WNK4 and this phosphorylation step reduces the inhibition of WNK4 on NCC
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 [98, 100]. Because SGK1 is sensitive to aldosterone, this pathway appears to be involved in the
5
6 activation of NCC by aldosterone [100]. The opposite is also true, because SGK1 knockout mice
7
8 failed to increase NCC activity during a low sodium diet [115].
9

10 11 12 13 14 ***Ubiquitin ligases***

15
16 Recent data indicate that Nedd4-2 is yet another player in the pathway by which aldosterone
17
18 activates NCC (**Figure 3**) [2, 99]. Nedd4-2 was shown to stimulate ubiquitylation of NCC and
19
20 decreased its activity and surface expression *in vitro* and *in vivo*, while SGK1 prevented these
21
22 effects [2]. The pathophysiological significance of the regulation of NCC by Nedd4-2 was shown
23
24 by the generation of inducible nephron-specific Nedd4-2 knockout mice [99]. These mice
25
26 exhibited salt-dependent hypertension that was characterized by upregulation of total and
27
28 phosphorylated NCC and sensitivity to thiazides. The deletion of Nedd4-2 also affected ENaC
29
30 and ROMK, which were down- and upregulated, respectively. This may explain the additional
31
32 characteristics of these mice, namely that they had a normal Na^+/K^+ balance and were not
33
34 hyperkalemic. Similar to Nedd4-2, Kelch-like 3 and Cullin 3 are also involved in ubiquitylation,
35
36 because they are components of an E3 ubiquitin ligase complex. Although mutations in Kelch-
37
38 like 3 and Cullin-3 cause hyperkalemic hypertension that is reversible with thiazides, these
39
40 proteins probably do not interact directly with NCC. Instead, Kelch-like 3 binds and
41
42 ubiquitinates WNK4 and the subsequent degradation of WNK4 would be expected to increase
43
44 NCC activity (**Figure 3**) [89, 106, 128, 132].
45
46
47
48
49
50
51
52
53
54

55 ***Other signaling molecules***

56
57 Although the network reviewed above is largely interconnected (**Figure 3**), additional NCC
58
59 regulatory pathways exist. One example is the regulation of NCC by phorbol esters [54]. This
60
61
62
63
64
65

1
2
3
4 effect is mediated through Ras guanyl-releasing protein 1 and ERK1/2, which stimulates
5
6 ubiquitylation and endocytosis of NCC [55]. Furthermore, NCC phosphorylation is not only
7
8 controlled by kinases but also by phosphatases including phosphatase 4 [33]. Finally, the process
9
10 that controls the phosphorylation of NCC may also cause less ubiquitylation, thereby increasing
11
12 the number of cotransporters available for phosphorylation [51].
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Relation to human disease

Gitelman syndrome

The clearest demonstration of the functional relevance of NCC comes from human monogenic diseases that affect NCC function (**Table 2**). Inactivating mutations in *SLC12A3* cause the so-called Gitelman syndrome [107]. Gitelman syndrome is an autosomal recessive disorder that is characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, hypocalciuria, and low to normal arterial blood pressure. Missense mutations account for approximately 59% of the mutations in Gitelman syndrome and compound heterozygosity is common [113, 123]. Gender and the type of mutation contribute to phenotypic variability, with males and patients with homozygous deep intronic mutations exhibiting a **more severe** phenotype [64, 65]. Novel mutations are still being identified in Gitelman syndrome and these genetic defects lead to impaired production, processing, insertion or regulation of the NCC protein (type I, II, III or IV mutations) [32, 113, 123]. Although Gitelman syndrome is usually a relatively benign disorder that often remains subclinical for many years, a recent report suggests that the electrolyte disorders associated with Gitelman syndrome may result in chronic kidney disease and glucose intolerance [113]. On the other hand, heterozygous mutations in NCC may prevent hypertension and cardiovascular diseases [52] and improve bone-density [17] likely because they induce mild sodium excretion and a positive calcium balance. NCC knockout mice recapitulate the phenotype of Gitelman syndrome, although some features become manifest only when the animals are challenged [73, 80, 105, 139]. In line with the current model of NCC regulation (**Figure 3**), genetically modified mice with overexpression of WNK4, deficiency in SPAK or its kinase domain, also exhibit features of Gitelman syndrome [61, 88, 94, 139], although such mutations have not been identified in humans. Gitelman syndrome should be differentiated from the more

1
2
3
4 severe Bartter syndrome, which results from mutations affecting NKCC2, and is characterized by
5
6 earlier onset of symptoms and hypercalciuria instead of hypocalciuria [47]. An intermediary
7
8 phenotype is caused by mutations in *CLCNKB* which encodes a basolateral chloride channel that
9
10 is expressed in both the thick ascending limb and the DCT (**Table 2**) [58]. **Disturbed**
11
12 **basolateral chloride efflux will indirectly impair apical NaCl transport through NKCC2**
13
14 **and NCC.**
15
16
17
18
19
20

21 *Familial hyperkalemic hypertension*

22
23 Familial hyperkalemic hypertension (FHHT) is the “mirror image” of Gitelman syndrome
24
25 because, in addition to hyperkalemia and hypertension, it is characterized by hypercalciuria and
26
27 metabolic acidosis [37]. Surprisingly, no activating mutations in *SLC12A3* have been reported.
28
29 Overexpression of NCC in transgenic mice also failed to induce hyperkalemic hypertension, but
30
31 this may have been due to the fact that phosphorylated NCC was not increased [74]. Similarly,
32
33 increasing NCC activity by inactivating KS-WNK1 was also not sufficient to cause
34
35 hyperkalemic hypertension, because it was associated with a compensatory decrease in ENaC
36
37 [38]. Instead, familial hyperkalemic hypertension is caused by mutations in the genes encoding
38
39 WNK1, WNK4, Kelch-like 3 or Cullin-3, which result in overactivity of NCC (**Table 2**) [7, 68,
40
41 131]. Because the WNKs regulate other transporters than NCC alone, these effects may also
42
43 contribute to the FHHT-phenotype [37]. Intronic deletions in the WNK1 gene cause
44
45 overexpression of WNK1 and therefore more inhibition of WNK4. The inhibition of WNK4 will
46
47 relieve the inhibition of SPAK and will activate NCC (**Figure 3**). Similarly, missense mutations
48
49 in the WNK4 gene give rise to a mutant protein that no longer inhibits SPAK resulting in NCC
50
51 activation. Mutations in *KLHL3* can be dominant or recessive and homozygous or heterozygous,
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 while the identified mutations in *CUL3* were dominant, heterozygous and often *de novo* [7].
5
6 Mutations in *KLHL3* and *CUL3* seem to abrogate ubiquitylation of targets normally bound by
7
8 *KLHL3* including WNK4 [106]. Of the different mutations causing FHHt, *CUL3* mutations have
9
10 the most severe phenotype, including the youngest onset of hypertension and the highest serum
11
12 potassium [7]. Another illustration that NCC activation is the final common pathway of the
13
14 FHHt mutations is the fact that these disorders are all exquisitely sensitive to treatment with
15
16 thiazide-type diuretics [71].
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Drugs influencing NCC activity

Drugs inhibiting NCC

Several commonly used drugs inhibit or stimulate NCC activity (**Table 1**). The sensitivity of NCC for thiazide diuretics is well known and characterizes this cotransporter. Thiazides, however, do not exclusively inhibit NCC, but also the sodium-dependent bicarbonate-chloride cotransporter in the cortical collecting duct [63]. Thiazide diuretics were incidentally discovered while searching for better carbonic anhydrase inhibitors [86]. They were implemented clinically in 1958, long before it became apparent that their primary target is NCC [81]. Thiazide diuretics are the logical drug of choice for diseases with NCC overactivity such as the rare disorder FHHt. However, the clinical indication for thiazide diuretics is much broader. In fact, thiazide diuretics are still among the most commonly used drugs to treat hypertension worldwide. Although the natriuretic effect of these drugs undoubtedly contributes to their antihypertensive effect, this response also seems to be translated to an effect on vascular tone [9-11]. In addition, thiazides may directly cause vasodilation possibly through vascular potassium channel activation [92]. In addition to hypertension, thiazide diuretics can also be used for sodium-retaining disorders such as heart failure, liver cirrhosis, nephrotic syndrome, and chronic kidney disease [8]. Because thiazide diuretics act in the tubular lumen, their action requires successful delivery to the DCT. This is mediated by active secretion of thiazide diuretics in the proximal tubule through organic anion transporter and multidrug resistance-associated protein 4 [39, 114]. This explains why a reduction in glomerular filtration rate results in reduced efficacy of thiazide diuretics. Patients with Gitelman syndrome also demonstrate a dramatically impaired natriuretic response to thiazides, a feature that may be used diagnostically [15]. The side-effect profile of thiazide diuretics resembles Gitelman syndrome with the exception of hyponatremia, which is only seen with thiazides [22, 24, 48].

Drugs stimulating NCC

Drugs *stimulating* NCC activity have also been identified recently and they include the calcineurin inhibitors cyclosporine and tacrolimus (**Table 1**) [44, 76]. Calcineurin inhibitors are potent immunosuppressive drugs that are used clinically to prevent rejection after transplantation and sometimes in autoimmune disorders. Although cyclosporine and tacrolimus have different intracellular binding proteins, they both activate NCC, and this effect therefore appears to be a class effect [45]. Again, cyclosporine and tacrolimus do not seem to activate NCC directly, but influence the WNKs [76]. This possibility was already suggested by the side-effect profile of these drugs, which is similar to the phenotype of FHHt. Of interest, calcineurin is a protein phosphatase and protein phosphatases were recently shown to regulate NCC [33]. We were able to illustrate the clinical relevance of NCC activation by tacrolimus by linking it to hypertension [44]. That is, tacrolimus failed to induce hypertension in NCC knockout mice, whereas it caused more severe hypertension in NCC transgenic mice. Furthermore, a thiazide diuretic caused a larger urinary chloride excretion in patients on tacrolimus than in healthy volunteers or patients on sirolimus (a different immunosuppressant). This enhanced chloriuretic response to a thiazide was interpreted as an indication of increased transporter activity [15]. Also, the expression of total and phosphorylated NCC was increased in the kidney biopsies of patients treated with tacrolimus. Of interest, a model of cyclosporine nephrotoxicity showed the opposite effect on NCC, but this was attributed to inactivation of the renin-angiotensin system [62]. Furosemide, which blocks sodium transport in the thick ascending limb but not in the DCT, also increases NCC abundance. This effect is likely caused by the loop-diuretic induced enhanced sodium delivery to the DCT and the activation of the renin-angiotensin system [1]. The up-regulation of NCC likely compensates for the furosemide effect and hence may contribute to the phenomenon

1
2
3
4 of loop-diuretic resistance which frequently develops during chronic treatment. As such it
5
6 provides the rationale for the combination of a loop-diuretic with a thiazide to overcome diuretic
7
8 resistance [8]. Furthermore, recent studies in rats suggested that the cytostatic drug cisplatin
9
10 decreases renal NCC abundance. However, this effect is likely attributed to a general toxic effect
11
12 on DCT cells, because also the expression of other DCT-specific proteins such as the magnesium
13
14 channel TRPM6 and the calcium- and magnesium-binding protein parvalbumin were decreased
15
16
17
18
19 [116].
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Perspectives

In this review we have highlighted several exciting new roles of NCC in sodium, potassium, and blood pressure regulation. These new insights have partly solved longstanding questions in physiology, but at the same time raise new questions. For example, although the model of NCC regulation is gaining more clarity (**Figure 3**), some of the interactions are still not well understood or even controversial. For example, WNK4 seems to be a negative regulator of NCC under some conditions, but may become a positive regulator in others [72]. The inhibition of NCC by dietary potassium may be mediated by WNK4 [87, 110, 120], but leaves the question open through which signal DCT cells “sense” dietary potassium. Pathophysiologically, the role of NCC in “essential” hypertension will likely remain a focus of future studies. The recent linkage of Cullin-3 and Kelch-like 3 to FHHt begs the question whether polymorphisms in these genes exist and whether they may contribute to human hypertension. The discovery that calcineurin inhibitors stimulate NCC to cause hypertension warrants a clinical study to evaluate whether thiazide diuretics are effective drugs to treat this side effect [44-46]. Especially for translational studies it will be important to have a measure of NCC activity *in vivo*. In addition to testing the response to a thiazide diuretic [15], the analysis of NCC in so-called urinary exosomes holds promise [43]. Urinary exosomes are vesicles derived from renal tubular epithelial cells that are thought to reflect the metabolic profile of these cells [93]. We recently showed that the abundance of phosphorylated NCC in urinary exosomes correlated with elevated aldosterone levels in animals and humans [117]. Although this review focused on NCC, sodium excretion by the kidney depends on many other sodium transporters, including NHE3, NKCC2, ENaC, and pendrin. Stimuli that activate NCC, sometimes also activate these other transporters, but an opposite, compensatory response may also occur [38, 84, 99]. In conclusion, the role of NCC in normal physiology and in the pathophysiology of hypertension is expanding and will

1
2
3
4 likely continue to do so in coming years. To fully grasp the potential of these insights for the
5
6 treatment of human disease will likely require a more complete understanding of the molecular
7
8 physiology of this fascinating cotransporter.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Grants

EJH is supported by the Dutch Kidney Foundation (KJPB 08.004) and the Netherlands

Organisation for Scientific Research (Veni). NvdL is supported by the Netherlands Foundation

for Cardiovascular Excellence. JL is supported by the Swiss National Science Foundation, the

Swiss National Centre in Competence in Research Kidney.CH, and the Zurich Centre for

Integrative Human Physiology.

Table 1: Hormones, metabolic stimuli and drugs influencing NCC activity

	Stimulus	Effect	References
Hormones	Angiotensin II	Stimulatory	[118]
	Aldosterone	Stimulatory¶	[53]
	Glucocorticoids	Stimulatory	[124]
	Vasopressin	Stimulatory	[83, 91, 104]
	Insulin	Stimulatory	[13, 57, 108, 109]
	Estrogen	Stimulatory	[125]
	Norepinephrine	Stimulatory	[82]
Metabolic stimuli	Dietary potassium	Inhibitory	[110, 120]
	Dietary sodium*	Inhibitory	[14, 103]
	Dietary magnesium*	Stimulatory	[25]
	Acidosis*	Stimulatory	[26]
Drugs	Thiazide diuretics	Inhibitory	[16, 23]
	Furosemide*	Stimulatory	[1]
	Tacrolimus	Stimulatory	[44]
	Cyclosporine†	Stimulatory	[76]
	Cisplatin	Inhibitory	[116]

Footnote: ¶ When high dietary K increases aldosterone, NCC may be inhibited; * Some of these effects may be mediated through aldosterone; † In a model of cyclosporine nephrotoxicity,

NCC was downregulated, but this may be attributed to kidney failure and reduced renin-angiotensin activity [76].

Table 2: Characteristics of mutations causing Gitelman syndrome or familial hyperkalemic hypertension

Disease	Gene	OMIM gene	Human chromosome location	Encoding protein	Major phenotype	Selected references
Gitelman (OMIM 263800)	<i>SLC12A3</i>	600968	16q13	NCC	Hypokalemic hypotension	[107]
	<i>CLCNKB</i>	602023	1p36.13	CLCNKB	Variable	[58]
FHHt* (OMIM 179820)	<i>WNK1</i>	605232	12p13	WNK1	Hyperkalemic hypertension	[131]
	<i>WNK4</i>	601844	17q21	WNK4	Hyperkalemic hypertension	[131]
	<i>KLHL3</i>	605775	5q31	Kelch-like 3	Hyperkalemic hypertension	[7]
	<i>CUL-3</i>	603136	2q36	Cullin-3	Hyperkalemic hypertension	[7, 68]

1
2
3
4 **Abbreviation:** * FHHt, familial hyperkalemic hypertension; OMIM, online Mendelian
5
6 inheritance in man.
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure legends

Figure 1: Model of transcellular transport in the early distal convoluted tubule (DCT). A kidney tubule is shown schematically on the left indicating the locations of DCT type 1 and type 2 (DCT1, DCT2) and the connecting tubule (CNT). The sodium chloride cotransporter (NCC) is primarily expressed in DCT1. A model of transcellular transport in DCT1 is shown on the right, including the apical transporters NCC and transient receptor potential channels TRPV5 (a calcium channel) and TRPM6 (a magnesium channel). On the basolateral side the sodium potassium ATPase pump is shown as well as the chloride channel ClC-Kb and the sodium-calcium channel NCX1. This figure was adapted from [5, 59].

Figure 2: Putative structure of the sodium chloride cotransporter. The twelve transmembrane domains are shown including the hydrophilic loop with the two glycosylation sites. A detailed image of the N-terminus is provided on the left showing the binding sites of γ -adducin and the kinases SPAK/OSR1. This figure was reproduced and adapted from [19] with kind permission.

Figure 3: Current model of sodium chloride cotransporter regulation by kinases and ubiquitinases. The various interactions of the NCC regulatory pathway are shown as arrows (stimulatory) or as lines ending with perpendicular lines (inhibitory). Phosphorylation is indicated with the symbol “P”, whereas ubiquitylation is shown as “U”. SPAK/OSR1, WNK4, kidney-specific WNK1 (KS-WNK1) and long WNK1 (L-WNK1, also called WNK1) are kinases. The role of mutant WNK4 in familial hyperkalemic hypertension (FHHT) is also shown, which overrides the inhibitory effect of wild-type WNK4 on SPAK/OSR1. Nedd4-2 is a ubiquitinase, while Cullin-3 and Kelch-like 3 interact in a ubiquitylation complex that likely

1
2
3
4 ubiquitinates WNK4. **Although WNK3 has been shown to interact with WNK4 and SPAK**
5 **[90, 135], its precise role in NCC regulation remains less clear and we therefore decided not**
6 **to include it.** See text for further details.
7
8
9

10
11
12
13
14
15 **Figure 4:** Inhibition of the sodium chloride cotransporter by dietary potassium (**“high K”**). The
16 results of our recent studies on the inhibitory effect of dietary potassium on NCC are shown
17 [110, 121]. Panel A shows that dietary potassium acutely downregulates phosphorylated NCC
18 but not total NCC. Conversely, panel B shows that a chronic high potassium diet primarily
19 decreased total NCC, but phosphorylated NCC less so. **The high potassium diet was 2% and**
20 **5%, respectively, and the low sodium diet was < 0.001% [110, 121].**
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH (2001) Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. *J Am Soc Nephrol* 12:1335-1341
2. Arroyo JP, Lagnaz D, Ronzaud C, Vazquez N, Ko BS, Moddes L, Ruffieux-Daidie D, Hausel P, Koesters R, Yang B, Stokes JB, Hoover RS, Gamba G, Staub O (2011) Nedd4-2 modulates renal Na⁺-Cl⁻ cotransporter via the aldosterone-SGK1-Nedd4-2 pathway. *J Am Soc Nephrol* 22:1707-1719
3. Arroyo JP, Ronzaud C, Lagnaz D, Staub O, Gamba G (2011) Aldosterone paradox: differential regulation of ion transport in distal nephron. *Physiology (Bethesda)* 26:115-123
4. Bazzini C, Vezzoli V, Sironi C, Dossena S, Ravasio A, De Biasi S, Garavaglia M, Rodighiero S, Meyer G, Fascio U, Furst J, Ritter M, Botta G, Paulmichl M (2005) Thiazide-sensitive NaCl-cotransporter in the intestine: possible role of hydrochlorothiazide in the intestinal Ca²⁺ uptake. *J Biol Chem* 280:19902-19910
5. Bindels RJ (2010) 2009 Homer W. Smith Award: Minerals in motion: from new ion transporters to new concepts. *J Am Soc Nephrol* 21:1263-1269
6. Bostanjoglo M, Reeves WB, Reilly RF, Velazquez H, Robertson N, Litwack G, Morsing P, Dorup J, Bachmann S, Ellison DH (1998) 11β-hydroxysteroid dehydrogenase, mineralocorticoid receptor, and thiazide-sensitive Na-Cl cotransporter expression by distal tubules. *J Am Soc Nephrol* 9:1347-1358
7. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Valimaki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP (2012) Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature* 482:98-102
8. Brater DC (1998) Diuretic therapy. *N Engl J Med* 339:387-395
9. Calo L, Davis PA, Semplicini A (2002) Reduced content of alpha subunit of Gq protein content in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. *Kidney Int* 61:353-354
10. Calo LA, Davis PA (2010) Number and function of circulating endothelial progenitor cells and calcitonin gene-related peptide in hypertension: support from and opportunities in Bartter's and Gitelman's syndromes patients. *J Hypertens* 28:2169-2170; author reply 2171
11. Calo LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, Davis PA, Palatini P, Pauletto P (2008) Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. *Nephrol Dial Transplant* 23:2804-2809
12. Castaneda-Bueno M, Vazquez N, Bustos-Jaimes I, Hernandez D, Rodriguez-Lobato E, Pacheco-Alvarez D, Carino-Cortes R, Moreno E, Bobadilla NA, Gamba G (2010) A single residue in transmembrane domain 11 defines the different affinity for thiazides

- 1
2
3
4 between the mammalian and flounder NaCl transporters. *Am J Physiol Renal Physiol* 299:F1111-1119
- 5
6
7 13. Chavez-Canales M, Arroyo JP, Ko B, Vazquez N, Bautista R, Castaneda-Bueno M,
8 Bobadilla NA, Hoover RS, Gamba G (2013) Insulin increases the functional activity of
9 the renal NaCl cotransporter. *J Hypertens* 31:303-311
- 10
11 14. Chiga M, Rai T, Yang SS, Ohta A, Takizawa T, Sasaki S, Uchida S (2008) Dietary salt
12 regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride
13 cotransporter through aldosterone. *Kidney Int* 74:1403-1409
- 14
15 15. Colussi G, Bettinelli A, Tedeschi S, De Ferrari ME, Syren ML, Borsa N, Mattiello C,
16 Casari G, Bianchetti MG (2007) A thiazide test for the diagnosis of renal tubular
17 hypokalemic disorders. *Clin J Am Soc Nephrol* 2:454-460
- 18
19 16. Costanzo LS (1985) Localization of diuretic action in microperfused rat distal tubules: Ca
20 and Na transport. *Am J Physiol* 248:F527-535
- 21
22 17. Cruz DN (2001) The renal tubular Na-Cl co-transporter (NCCT): a potential genetic link
23 between blood pressure and bone density? *Nephrol Dial Transplant* 16:691-694
- 24
25 18. de Jong JC, Willems PH, Mooren FJ, van den Heuvel LP, Knoers NV, Bindels RJ (2003)
26 The structural unit of the thiazide-sensitive NaCl cotransporter is a homodimer. *J Biol*
27 *Chem* 278:24302-24307
- 28
29 19. Dimke H (2011) Exploring the intricate regulatory network controlling the thiazide-
30 sensitive NaCl cotransporter (NCC). *Pflugers Arch* 462:767-777
- 31
32 20. Dvorak MM, De Joussineau C, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp
33 PJ, Riccardi D (2007) Thiazide diuretics directly induce osteoblast differentiation and
34 mineralized nodule formation by interacting with a sodium chloride co-transporter in
35 bone. *J Am Soc Nephrol* 18:2509-2516
- 36
37 21. Ellison DH (2012) Adaptation in Gitelman syndrome: "we just want to pump you up".
38 *Clin J Am Soc Nephrol* 7:379-382
- 39
40 22. Ellison DH, Loffing J (2009) Thiazide effects and adverse effects: insights from
41 molecular genetics. *Hypertension* 54:196-202
- 42
43 23. Ellison DH, Velazquez H, Wright FS (1987) Thiazide-sensitive sodium chloride
44 cotransport in early distal tubule. *Am J Physiol* 253:F546-554
- 45
46 24. Ernst ME, Moser M (2009) Use of diuretics in patients with hypertension. *N Engl J Med*
47 361:2153-2164
- 48
49 25. Fanestil DD, Hyde RH, Blakely P, Vaughn DA (1999) Dietary magnesium, not calcium,
50 regulates renal thiazide receptor. *J Am Soc Nephrol* 10:458-463
- 51
52 26. Faroqui S, Sheriff S, Amlal H (2006) Metabolic acidosis has dual effects on sodium
53 handling by rat kidney. *Am J Physiol Renal Physiol* 291:F322-331
- 54
55 27. Frindt G, Houde V, Palmer LG (2011) Conservation of Na⁺ vs. K⁺ by the rat cortical
56 collecting duct. *Am J Physiol Renal Physiol* 301:F14-20
- 57
58 28. Frindt G, Palmer LG (2009) Surface expression of sodium channels and transporters in
59 rat kidney: effects of dietary sodium. *Am J Physiol Renal Physiol* 297:F1249-1255
- 60
61 29. Gamba G (2009) The thiazide-sensitive Na⁺-Cl⁻ cotransporter: molecular biology,
62 functional properties, and regulation by WNKs. *Am J Physiol Renal Physiol* 297:F838-
63 848
- 64
65 30. Gamba G, Miyanoshita A, Lombardi M, Lytton J, Lee WS, Hediger MA, Hebert SC
(1994) Molecular cloning, primary structure, and characterization of two members of the

- mammalian electroneutral sodium-(potassium)-chloride cotransporter family expressed in kidney. *J Biol Chem* 269:17713-17722
31. Gamba G, Saltzberg SN, Lombardi M, Miyanoshita A, Lytton J, Hediger MA, Brenner BM, Hebert SC (1993) Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter. *Proc Natl Acad Sci U S A* 90:2749-2753
 32. Glaudemans B, Yntema HG, San-Cristobal P, Schoots J, Pfundt R, Kamsteeg EJ, Bindels RJ, Knoers NV, Hoenderop JG, Hoefsloot LH (2012) Novel NCC mutants and functional analysis in a new cohort of patients with Gitelman syndrome. *Eur J Hum Genet* 20:263-270
 33. Glover M, Mercier Zuber A, Figg N, O'Shaughnessy KM (2010) The activity of the thiazide-sensitive Na(+)-Cl(-) cotransporter is regulated by protein phosphatase PP4. *Can J Physiol Pharmacol* 88:986-995
 34. Glover M, Zuber AM, O'Shaughnessy KM (2009) Renal and brain isoforms of WNK3 have opposite effects on NCCT expression. *J Am Soc Nephrol* 20:1314-1322
 35. Golbang AP, Cope G, Hamad A, Murthy M, Liu CH, Cuthbert AW, O'Shaughnessy K M (2006) Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved. *Am J Physiol Renal Physiol* 291:F1369-1376
 36. Grimm PR, Taneja TK, Liu J, Coleman R, Chen YY, Delpire E, Wade JB, Welling PA (2012) SPAK isoforms and OSR1 regulate sodium-chloride co-transporters in a nephron-specific manner. *J Biol Chem* 287:37673-37690
 37. Hadchouel J, Delaloy C, Faure S, Achard JM, Jeunemaitre X (2006) Familial hyperkalemic hypertension. *J Am Soc Nephrol* 17:208-217
 38. Hadchouel J, Soukaseum C, Busst C, Zhou XO, Baudrie V, Zurrer T, Cambillau M, Elghozi JL, Lifton RP, Loffing J, Jeunemaitre X (2010) Decreased ENaC expression compensates the increased NCC activity following inactivation of the kidney-specific isoform of WNK1 and prevents hypertension. *Proc Natl Acad Sci U S A* 107:18109-18114
 39. Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y (2007) Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. *J Am Soc Nephrol* 18:37-45
 40. Hebert SC, Mount DB, Gamba G (2004) Molecular physiology of cation-coupled Cl⁻-cotransport: the SLC12 family. *Pflugers Arch* 447:580-593
 41. Hoorn EJ, Ellison DH (2012) WNK kinases and the kidney. *Exp Cell Res* 318:1020-1026
 42. Hoorn EJ, Nelson JH, McCormick JA, Ellison DH (2011) The WNK kinase network regulating sodium, potassium, and blood pressure. *J Am Soc Nephrol* 22:605-614
 43. Hoorn EJ, Pisitkun T, Zietse R, Gross P, Frokiaer J, Wang NS, Gonzales PA, Star RA, Knepper MA (2005) Prospects for urinary proteomics: exosomes as a source of urinary biomarkers. *Nephrology (Carlton)* 10:283-290
 44. Hoorn EJ, Walsh SB, McCormick JA, Furstenberg A, Yang CL, Roeschel T, Paliege A, Howie AJ, Conley J, Bachmann S, Unwin RJ, Ellison DH (2011) The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. *Nat Med* 17:1304-1309
 45. Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. *J Nephrol* 25:269-275

- 1
- 2
- 3
- 4 46. Hoorn EJ, Walsh SB, Unwin RJ, Ellison DH (2012) Hypertension after kidney
5 transplantation: calcineurin inhibitors increase salt-sensitivity. *J Hypertens* 30:832-833;
6 author reply 833-834
- 7
- 8 47. Hoorn EJ, Zietse R (2013) Disorders of calcium and magnesium balance: a physiology-
9 based approach. *Pediatr Nephrol* 28:1195-1206
- 10 48. Hoorn EJ, Zietse R (2008) Hyponatremia revisited: translating physiology to practice.
11 *Nephron Physiol* 108:p46-59
- 12
- 13 49. Hoover RS (2011) Angiotensin II: a candidate for an aldosterone-independent mediator
14 of potassium preservation during volume depletion. *Kidney Int* 79:377-379
- 15 50. Hoover RS, Poch E, Monroy A, Vazquez N, Nishio T, Gamba G, Hebert SC (2003) N-
16 Glycosylation at two sites critically alters thiazide binding and activity of the rat thiazide-
17 sensitive Na(+):Cl(-) cotransporter. *J Am Soc Nephrol* 14:271-282
- 18 51. Hossain Khan MZ, Sohara E, Ohta A, Chiga M, Inoue Y, Isobe K, Wakabayashi M, Oi
19 K, Rai T, Sasaki S, Uchida S (2012) Phosphorylation of Na-Cl cotransporter by OSR1
20 and SPAK kinases regulates its ubiquitination. *Biochem Biophys Res Commun* 425:456-
21 461
- 22
- 23 52. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW,
24 Levy D, Lifton RP (2008) Rare independent mutations in renal salt handling genes
25 contribute to blood pressure variation. *Nat Genet* 40:592-599
- 26 53. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA (1998) The
27 thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. *Proc Natl Acad*
28 *Sci U S A* 95:14552-14557
- 29
- 30 54. Ko B, Joshi LM, Cooke LL, Vazquez N, Musch MW, Hebert SC, Gamba G, Hoover RS
31 (2007) Phorbol ester stimulation of RasGRP1 regulates the sodium-chloride cotransporter
32 by a PKC-independent pathway. *Proc Natl Acad Sci U S A* 104:20120-20125
- 33 55. Ko B, Kamsteeg EJ, Cooke LL, Moddes LN, Deen PM, Hoover RS (2010) RasGRP1
34 stimulation enhances ubiquitination and endocytosis of the sodium-chloride
35 cotransporter. *Am J Physiol Renal Physiol* 299:F300-309
- 36 56. Ko B, Mistry AC, Hanson LN, Mallick R, Wynne BM, Thai TL, Bailey JL, Klein JD,
37 Hoover RS (2013) Aldosterone Acutely Stimulates Ncc Activity Via a Spak-Mediated
38 Pathway. *Am J Physiol Renal Physiol*
- 39 57. Komers R, Rogers S, Oyama TT, Xu B, Yang CL, McCormick J, Ellison DH (2012)
40 Enhanced phosphorylation of Na(+)-Cl- co-transporter in experimental metabolic
41 syndrome: role of insulin. *Clin Sci (Lond)* 123:635-647
- 42 58. Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas-Poussou R,
43 Lakings A, Ruf R, Deschenes G, Antignac C, Guay-Woodford L, Knoers NV, Seyberth
44 HW, Feldmann D, Hildebrandt F (2000) Mutations in the chloride channel gene
45 CLCNKB as a cause of classic Bartter syndrome. *J Am Soc Nephrol* 11:1449-1459
- 46 59. Kriz W, Bankir L (1988) A standard nomenclature for structures of the kidney. The Renal
47 Commission of the International Union of Physiological Sciences (IUPS). *Kidney Int*
48 33:1-7
- 49 60. Kunau RT, Jr., Weller DR, Webb HL (1975) Clarification of the site of action of
50 chlorothiazide in the rat nephron. *J Clin Invest* 56:401-407
- 51 61. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson-
52 Williams C, Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP (2006) Wnk4
53
54
55
56
57
58
59
60
61
62
63
64
65

- controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. *Nat Genet* 38:1124-1132
62. Ledeganck KJ, Boulet GA, Horvath CA, Vinckx M, Bogers JJ, Van Den Bossche R, Verpooten GA, De Winter BY (2011) Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment. *Am J Physiol Renal Physiol* 301:F486-493
63. Leviel F, Hubner CA, Houillier P, Morla L, El Moghrabi S, Brideau G, Hassan H, Parker MD, Kurth I, Kougioumtzes A, Sinning A, Pech V, Riemondy KA, Miller RL, Hummler E, Shull GE, Aronson PS, Doucet A, Wall SM, Chambrey R, Eladari D (2010) The Na⁺-dependent chloride-bicarbonate exchanger SLC4A8 mediates an electroneutral Na⁺ reabsorption process in the renal cortical collecting ducts of mice. *J Clin Invest* 120:1627-1635
64. Lin SH, Cheng NL, Hsu YJ, Halperin ML (2004) Intrafamilial phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. *Am J Kidney Dis* 43:304-312
65. Lin SH, Shiang JC, Huang CC, Yang SS, Hsu YJ, Cheng CJ (2005) Phenotype and genotype analysis in Chinese patients with Gitelman's syndrome. *J Clin Endocrinol Metab* 90:2500-2507
66. Loffing J, Vallon V, Loffing-Cueni D, Aregger F, Richter K, Pietri L, Bloch-Faure M, Hoenderop JG, Shull GE, Meneton P, Kaissling B (2004) Altered renal distal tubule structure and renal Na⁽⁺⁾ and Ca⁽²⁺⁾ handling in a mouse model for Gitelman's syndrome. *J Am Soc Nephrol* 15:2276-2288
67. Loffing J, Zecevic M, Feraille E, Kaissling B, Asher C, Rossier BC, Firestone GL, Pearce D, Verrey F (2001) Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. *Am J Physiol Renal Physiol* 280:F675-682
68. Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, Vidal-Petiot E, Soukaseum C, Mandet C, Broux F, Chabre O, Delahousse M, Esnault V, Fiquet B, Houillier P, Bagnis CI, Koenig J, Konrad M, Landais P, Mourani C, Niaudet P, Probst V, Thauvin C, Unwin RJ, Soroka SD, Ehret G, Ossowski S, Caulfield M, International Consortium for Blood P, Bruneval P, Estivill X, Froguel P, Hadchouel J, Schott JJ, Jeunemaitre X (2012) KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. *Nat Genet* 44:456-460, S451-453
69. Masilamani S, Wang X, Kim GH, Brooks H, Nielsen J, Nielsen S, Nakamura K, Stokes JB, Knepper MA (2002) Time course of renal Na-K-ATPase, NHE3, NKCC2, NCC, and ENaC abundance changes with dietary NaCl restriction. *Am J Physiol Renal Physiol* 283:F648-657
70. Mastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, Ballabio A, Casari G (1996) Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter (SLC12A3). *Genomics* 35:486-493
71. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z (2002) Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. *J Clin Endocrinol Metab* 87:3248-3254

- 1
2
3
4 72. McCormick JA, Ellison DH (2011) The WNKs: atypical protein kinases with pleiotropic
5 actions. *Physiol Rev* 91:177-219
6
7 73. McCormick JA, Mutig K, Nelson JH, Saritas T, Hoorn EJ, Yang CL, Rogers S, Curry J,
8 Delpire E, Bachmann S, Ellison DH (2011) A SPAK isoform switch modulates renal salt
9 transport and blood pressure. *Cell Metab* 14:352-364
10
11 74. McCormick JA, Nelson JH, Yang CL, Curry JN, Ellison DH (2011) Overexpression of
12 the sodium chloride cotransporter is not sufficient to cause familial hyperkalemic
13 hypertension. *Hypertension* 58:888-894
14
15 75. McDonough AA (2010) Mechanisms of proximal tubule sodium transport regulation that
16 link extracellular fluid volume and blood pressure. *Am J Physiol Regul Integr Comp*
17 *Physiol* 298:R851-861
18
19 76. Melnikov S, Mayan H, Uchida S, Holtzman EJ, Farfel Z (2011) Cyclosporine metabolic
20 side effects: association with the WNK4 system. *Eur J Clin Invest* 41:1113-1120
21
22 77. Meneton P, Loffing J, Warnock DG (2004) Sodium and potassium handling by the
23 aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule.
24 *Am J Physiol Renal Physiol* 287:F593-601
25
26 78. Moreno E, Cristobal PS, Rivera M, Vazquez N, Bobadilla NA, Gamba G (2006) Affinity-
27 defining domains in the Na-Cl cotransporter: a different location for Cl⁻ and thiazide
28 binding. *J Biol Chem* 281:17266-17275
29
30 79. Moriguchi T, Urushiyama S, Hisamoto N, Iemura S, Uchida S, Natsume T, Matsumoto
31 K, Shibuya H (2005) WNK1 regulates phosphorylation of cation-chloride-coupled
32 cotransporters via the STE20-related kinases, SPAK and OSR1. *J Biol Chem* 280:42685-
33 42693
34
35 80. Morris RG, Hoorn EJ, Knepper MA (2006) Hypokalemia in a mouse model of Gitelman's
36 syndrome. *Am J Physiol Renal Physiol* 290:F1416-1420
37
38 81. Moser M, Feig PU (2009) Fifty years of thiazide diuretic therapy for hypertension. *Arch*
39 *Intern Med* 169:1851-1856
40
41 82. Mu S, Shimosawa T, Ogura S, Wang H, Uetake Y, Kawakami-Mori F, Marumo T,
42 Yatomi Y, Geller DS, Tanaka H, Fujita T (2011) Epigenetic modulation of the renal beta-
43 adrenergic-WNK4 pathway in salt-sensitive hypertension. *Nat Med* 17:573-580
44
45 83. Mutig K, Saritas T, Uchida S, Kahl T, Borowski T, Paliege A, Bohlick A, Bleich M,
46 Shan Q, Bachmann S (2010) Short-term stimulation of the thiazide-sensitive Na⁺-Cl⁻-
47 cotransporter by vasopressin involves phosphorylation and membrane translocation. *Am*
48 *J Physiol Renal Physiol* 298:F502-509
49
50 84. Nguyen MT, Lee DH, Delpire E, McDonough AA (2013) Differential Regulation of Na⁺-
51 Transporters along Nephron during AngII-Dependent Hypertension: Distal Stimulation
52 Counteracted by Proximal Inhibition. *Am J Physiol Renal Physiol*
53
54 85. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ (2005)
55 Enhanced passive Ca²⁺ reabsorption and reduced Mg²⁺ channel abundance explains
56 thiazide-induced hypocalciuria and hypomagnesemia. *J Clin Invest* 115:1651-1658
57
58 86. Novello FC, Sprague JM (1957) Benzothiadiazine dioxides as novel diuretics. *J Am*
59 *Chem Soc* 79:2028- 2029
60
61 87. O'Reilly M, Marshall E, Macgillivray T, Mittal M, Xue W, Kenyon CJ, Brown RW
62 (2006) Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo. *J*
63 *Am Soc Nephrol* 17:2402-2413
64
65


- 1
- 2
- 3
- 4 88. Ohta A, Rai T, Yui N, Chiga M, Yang SS, Lin SH, Sohara E, Sasaki S, Uchida S (2009)
- 5 Targeted disruption of the *Wnk4* gene decreases phosphorylation of Na-Cl cotransporter,
- 6 increases Na excretion and lowers blood pressure. *Hum Mol Genet* 18:3978-3986
- 7
- 8 89. Ohta A, Schumacher FR, Mehellou Y, Johnson C, Knebel A, Macartney TJ, Wood NT,
- 9 Alessi DR, Kurz T (2013) The CUL3-KLHL3 E3 ligase complex mutated in Gordon's
- 10 hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing
- 11 mutations in KLHL3 and WNK4 disrupt interaction. *Biochem J* 451:111-122
- 12
- 13 90. Pacheco-Alvarez D, Vazquez N, Castaneda-Bueno M, de-Los-Heros P, Cortes-Gonzalez
- 14 C, Moreno E, Meade P, Bobadilla NA, Gamba G (2012) WNK3-SPAK interaction is
- 15 required for the modulation of NCC and other members of the SLC12 family. *Cell*
- 16 *Physiol Biochem* 29:291-302
- 17
- 18 91. Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton RA (2010) Vasopressin
- 19 induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the
- 20 distal convoluted tubule. *Kidney Int* 78:160-169
- 21
- 22 92. Pickkers P, Hughes AD, Russel FG, Thien T, Smits P (1998) Thiazide-induced
- 23 vasodilation in humans is mediated by potassium channel activation. *Hypertension*
- 24 32:1071-1076
- 25
- 26 93. Pisitkun T, Shen RF, Knepper MA (2004) Identification and proteomic profiling of
- 27 exosomes in human urine. *Proc Natl Acad Sci U S A* 101:13368-13373
- 28
- 29 94. Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, Jovanovic S, Jovanovic A,
- 30 O'Shaughnessy KM, Alessi DR (2010) Role of the WNK-activated SPAK kinase in
- 31 regulating blood pressure. *EMBO Mol Med* 2:63-75
- 32
- 33 95. Renfro JL (1977) Interdependence of Active Na⁺ and Cl⁻ transport by the isolated
- 34 urinary bladder of the teleost, *Pseudopleuronectes americanus*. *J Exp Zool* 199:383-390
- 35
- 36 96. Renfro JL (1975) Water and ion transport by the urinary bladder of the teleost
- 37 *Pseudopleuronectes americanus*. *Am J Physiol* 228:52-61
- 38
- 39 97. Rinehart J, Kahle KT, de Los Heros P, Vazquez N, Meade P, Wilson FH, Hebert SC,
- 40 Gimenez I, Gamba G, Lifton RP (2005) WNK3 kinase is a positive regulator of NKCC2
- 41 and NCC, renal cation-Cl⁻ cotransporters required for normal blood pressure
- 42 homeostasis. *Proc Natl Acad Sci U S A* 102:16777-16782
- 43
- 44 98. Ring AM, Leng Q, Rinehart J, Wilson FH, Kahle KT, Hebert SC, Lifton RP (2007) An
- 45 SGK1 site in WNK4 regulates Na⁺ channel and K⁺ channel activity and has implications
- 46 for aldosterone signaling and K⁺ homeostasis. *Proc Natl Acad Sci U S A* 104:4025-4029
- 47
- 48 99. Ronzaud C, Loffing-Cueni D, Hausel P, Debonneville A, Malsure SR, Fowler-Jaeger N,
- 49 Boase NA, Perrier R, Maillard M, Yang B, Stokes JB, Koesters R, Kumar S, Hummler E,
- 50 Loffing J, Staub O (2013) Renal tubular NEDD4-2 deficiency causes NCC-mediated salt-
- 51 dependent hypertension. *J Clin Invest* 123:657-665
- 52
- 53 100. Rozansky DJ, Cornwall T, Subramanya AR, Rogers S, Yang YF, David LL, Zhu X,
- 54 Yang CL, Ellison DH (2009) Aldosterone mediates activation of the thiazide-sensitive
- 55 Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. *J Clin Invest*
- 56 119:2601-2612
- 57
- 58 101. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH,
- 59 Chari D, Kahle KT, Leng Q, Bobadilla NA, Hebert SC, Alessi DR, Lifton RP, Gamba G
- 60 (2009) Angiotensin II signaling increases activity of the renal Na-Cl cotransporter
- 61 through a WNK4-SPAK-dependent pathway. *Proc Natl Acad Sci U S A* 106:4384-4389
- 62
- 63
- 64
- 65

102. San-Cristobal P, Ponce-Coria J, Vazquez N, Bobadilla NA, Gamba G (2008) WNK3 and WNK4 amino-terminal domain defines their effect on the renal Na⁺-Cl⁻ cotransporter. *Am J Physiol Renal Physiol* 295:F1199-1206
103. Sandberg MB, Maunsbach AB, McDonough AA (2006) Redistribution of distal tubule Na⁺-Cl⁻ cotransporter (NCC) in response to a high-salt diet. *Am J Physiol Renal Physiol* 291:F503-508
104. Saritas T, Borschewski A, McCormick JA, Paliege A, Dathe C, Uchida S, Terker A, Himmerkus N, Bleich M, Demaretz S, Laghmani K, Delpire E, Ellison DH, Bachmann S, Mutig K (2013) SPAK differentially mediates vasopressin effects on sodium cotransporters. *J Am Soc Nephrol* 24:407-418
105. Schultheis PJ, Lorenz JN, Meneton P, Nieman ML, Riddle TM, Flagella M, Duffy JJ, Doetschman T, Miller ML, Shull GE (1998) Phenotype resembling Gitelman's syndrome in mice lacking the apical Na⁺-Cl⁻ cotransporter of the distal convoluted tubule. *J Biol Chem* 273:29150-29155
106. Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP (2013) Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. *Proc Natl Acad Sci U S A* 110:7838-7843
107. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP (1996) Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. *Nat Genet* 12:24-30
108. Sohara E, Rai T, Yang SS, Ohta A, Naito S, Chiga M, Nomura N, Lin SH, Vandewalle A, Ohta E, Sasaki S, Uchida S (2011) Acute insulin stimulation induces phosphorylation of the Na-Cl cotransporter in cultured distal mpkDCT cells and mouse kidney. *PLoS One* 6:e24277
109. Song J, Hu X, Riazzi S, Tiwari S, Wade JB, Ecelbarger CA (2006) Regulation of blood pressure, the epithelial sodium channel (ENaC), and other key renal sodium transporters by chronic insulin infusion in rats. *Am J Physiol Renal Physiol* 290:F1055-1064
110. Sorensen MV, Grossmann S, Roesinger M, Gresko N, Todkar AP, Barmettler G, Ziegler U, Odermatt A, Loffing-Cueni D, Loffing J (2013) Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice. *Kidney Int* 83:811-824
111. Stokes JB (1984) Sodium chloride absorption by the urinary bladder of the winter flounder. A thiazide-sensitive, electrically neutral transport system. *J Clin Invest* 74:7-16
112. Subramanya AR, Yang CL, McCormick JA, Ellison DH (2006) WNK kinases regulate sodium chloride and potassium transport by the aldosterone-sensitive distal nephron. *Kidney Int* 70:630-634
113. Tseng MH, Yang SS, Hsu YJ, Fang YW, Wu CJ, Tsai JD, Hwang DY, Lin SH (2012) Genotype, phenotype, and follow-up in Taiwanese patients with salt-losing tubulopathy associated with SLC12A3 mutation. *J Clin Endocrinol Metab* 97:E1478-1482
114. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK (2008) Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. *Am J Physiol Renal Physiol* 294:F867-873
115. Vallon V, Schroth J, Lang F, Kuhl D, Uchida S (2009) Expression and phosphorylation of the Na⁺-Cl⁻ cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. *Am J Physiol Renal Physiol* 297:F704-712

- 1
2
3
4 116. van Angelen AA, Glaudemans B, van der Kemp AW, Hoenderop JG, Bindels RJ (2013)
5 Cisplatin-induced injury of the renal distal convoluted tubule is associated with
6 hypomagnesaemia in mice. *Nephrol Dial Transplant* 28:879-889
- 7 117. van der Lubbe N, Jansen PM, Salih M, Fenton RA, van den Meiracker AH, Danser AH,
8 Zietse R, Hoorn EJ (2012) The phosphorylated sodium chloride cotransporter in urinary
9 exosomes is superior to prostaticin as a marker for aldosteronism. *Hypertension* 60:741-
10 748
- 11 118. van der Lubbe N, Lim CH, Fenton RA, Meima ME, Jan Danser AH, Zietse R, Hoorn EJ
12 (2011) Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride
13 cotransporter independent of aldosterone. *Kidney Int* 79:66-76
- 14 119. van der Lubbe N, Lim CH, Meima ME, van Veghel R, Rosenbaek LL, Mutig K, Danser
15 AH, Fenton RA, Zietse R, Hoorn EJ (2012) Aldosterone does not require angiotensin II
16 to activate NCC through a WNK4-SPAK-dependent pathway. *Pflugers Arch* 463:853-
17 863
- 18 120. Van der Lubbe N, Moes A, Rosenbaek LL, Schoep S, Meima ME, Danser AH, Fenton
19 RA, Zietse R, Hoorn EJ (2013) Potassium-induced natriuresis is preserved during sodium
20 depletion and accompanied by inhibition of the sodium chloride cotransporter. In revision
- 21 121. van der Lubbe N, Moes AD, Rosenbaek LL, Schoep S, Meima ME, Danser AH, Fenton
22 RA, Zietse R, Hoorn EJ (2013) K⁺-induced natriuresis is preserved during Na⁺ depletion
23 and accompanied by inhibition of the Na⁺-Cl⁻ cotransporter. *Am J Physiol Renal Physiol*
24 305:F1177-1188
- 25 122. van der Lubbe N, Zietse R, Hoorn EJ (2013) Effects of angiotensin II on kinase-mediated
26 sodium and potassium transport in the distal nephron. *Curr Opin Nephrol Hypertens*
27 22:120-126
- 28 123. Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart
29 B, Bridoux F, Unwin R, Moulin B, Haymann JP, Vantuyghem MC, Rigotherier C, Dussol B,
30 Godin M, Nivet H, Dubourg L, Tack I, Gimenez-Roqueplo AP, Houillier P, Blanchard A,
31 Devuyst O, Jeunemaitre X (2011) Spectrum of mutations in Gitelman syndrome. *J Am*
32 *Soc Nephrol* 22:693-703
- 33 124. Velazquez H, Bartiss A, Bernstein P, Ellison DH (1996) Adrenal steroids stimulate
34 thiazide-sensitive NaCl transport by rat renal distal tubules. *Am J Physiol* 270:F211-219
- 35 125. Verlander JW, Tran TM, Zhang L, Kaplan MR, Hebert SC (1998) Estradiol enhances
36 thiazide-sensitive NaCl cotransporter density in the apical plasma membrane of the distal
37 convoluted tubule in ovariectomized rats. *J Clin Invest* 101:1661-1669
- 38 126. Wagner CA, Loffing-Cueni D, Yan Q, Schulz N, Fakitsas P, Carrel M, Wang T, Verrey
39 F, Geibel JP, Giebisch G, Hebert SC, Loffing J (2008) Mouse model of type II Bartter's
40 syndrome. II. Altered expression of renal sodium- and water-transporting proteins. *Am J*
41 *Physiol Renal Physiol* 294:F1373-1380
- 42 127. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S,
43 Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F
44 (2001) Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel
45 (ENaC) and CFTR: implications for cystic fibrosis. *Cell Physiol Biochem* 11:209-218
- 46 128. Wakabayashi M, Mori T, Isobe K, Sohara E, Susa K, Araki Y, Chiga M, Kikuchi E,
47 Nomura N, Mori Y, Matsuo H, Murata T, Nomura S, Asano T, Kawaguchi H, Nonoyama
48 S, Rai T, Sasaki S, Uchida S (2013) Impaired KLHL3-mediated ubiquitination of WNK4
49 causes human hypertension. *Cell Rep* 3:858-868
- 50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 129. Wei Y, Zamilowicz B, Satlin LM, Wang WH (2007) Angiotensin II inhibits the ROMK-
5 like small conductance K channel in renal cortical collecting duct during dietary
6 potassium restriction. *J Biol Chem* 282:6455-6462
7
8 130. Welling PA, Chang YP, Delpire E, Wade JB (2010) Multigene kinase network, kidney
9 transport, and salt in essential hypertension. *Kidney Int* 77:1063-1069
10
11 131. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I,
12 Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin
13 RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP (2001) Human
14 hypertension caused by mutations in WNK kinases. *Science* 293:1107-1112
15
16 132. Wu G, Peng JB (2013) Disease-causing mutations in KLHL3 impair its effect on WNK4
17 degradation. *FEBS Lett* 587:1717-1722
18
19 133. Xu JZ, Hall AE, Peterson LN, Bienkowski MJ, Eessalu TE, Hebert SC (1997)
20 Localization of the ROMK protein on apical membranes of rat kidney nephron segments.
21 *Am J Physiol* 273:F739-748
22
23 134. Yang CL, Angell J, Mitchell R, Ellison DH (2003) WNK kinases regulate thiazide-
24 sensitive Na-Cl cotransport. *J Clin Invest* 111:1039-1045
25
26 135. Yang CL, Zhu X, Ellison DH (2007) The thiazide-sensitive Na-Cl cotransporter is
27 regulated by a WNK kinase signaling complex. *J Clin Invest* 117:3403-3411
28
29 136. Yang CL, Zhu X, Wang Z, Subramanya AR, Ellison DH (2005) Mechanisms of WNK1
30 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. *J Clin*
31 *Invest* 115:1379-1387
32
33 137. Yang LE, Sandberg MB, Can AD, Pihakaski-Maunsbach K, McDonough AA (2008)
34 Effects of dietary salt on renal Na⁺ transporter subcellular distribution, abundance, and
35 phosphorylation status. *Am J Physiol Renal Physiol* 295:F1003-1016
36
37 138. Yang SS, Fang YW, Tseng MH, Chu PY, Yu IS, Wu HC, Lin SW, Chau T, Uchida S,
38 Sasaki S, Lin YF, Sytwu HK, Lin SH (2013) Phosphorylation regulates NCC stability
39 and transporter activity in vivo. *J Am Soc Nephrol* 24:1587-1597
40
41 139. Yang SS, Lo YF, Wu CC, Lin SW, Yeh CJ, Chu P, Sytwu HK, Uchida S, Sasaki S, Lin
42 SH (2010) SPAK-knockout mice manifest Gitelman syndrome and impaired
43 vasoconstriction. *J Am Soc Nephrol* 21:1868-1877
44
45 140. Yue P, Sun P, Lin DH, Pan C, Xing W, Wang W (2011) Angiotensin II diminishes the
46 effect of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. *Kidney Int*
47 79:423-431
48
49 141. Zhou B, Wang D, Feng X, Zhang Y, Wang Y, Zhuang J, Zhang X, Chen G, Delpire E,
50 Gu D, Cai H (2012) WNK4 inhibits NCC protein expression through MAPK ERK1/2
51 signaling pathway. *Am J Physiol Renal Physiol* 302:F533-539
52
53 142. Zhou B, Zhuang J, Gu D, Wang H, Cebotaru L, Guggino WB, Cai H (2010) WNK4
54 enhances the degradation of NCC through a sortilin-mediated lysosomal pathway. *J Am*
55 *Soc Nephrol* 21:82-92
56
57
58
59
60
61
62
63
64
65

Figure 1
[Click here to download high resolution image](#)



Figure

[Click here to download high resolution image](#)




Figure 3
[Click here to download high resolution image](#)

